<DOC>
	<DOCNO>NCT02327351</DOCNO>
	<brief_summary>Treatment Study ass safety efficiency T cell receptor ( TCR ) alfa beta deplete graft hematopoietic stem cell transplantation ( HSCT ) haploidentical unrelated donor patient primary immunodeficiency disease</brief_summary>
	<brief_title>TCR Alpha/Beta Depletion HSCT From Haploidentical Unrelated Donors Treatment PID</brief_title>
	<detailed_description>Infections , graft versus host disease ( GVHD ) associate morbidity mortality remain significant problem unrelated haploidentical hematopoietic stem sell transplantation ( HSCT ) patient primary immunodeficiency disease ( PID ) . In study hypothesis transplantation TCR alfa beta deplete peripheral blood stem cell ( PBSC ) would offer advantage use positively select CD34+ stem cell haploidentical HSCT non-manipulated graft unrelated HSCT . The purpose study evaluate safety efficiency selective infusion TCR alfa beta T cell deplete graft pediatric patient PID receive HSCT haploidentical unrelated donor .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<criteria>Patients age â‰¥ 1 month &lt; 19 year Patients diagnose Primary Immunodeficiency Diseases eligible allogeneic transplantation lack relate HLAmatched donor Lansky/Karnofsky score &gt; 40 , WHO &gt; 4 Signed write informed consent Dysfunction liver ( ALT/AST &gt; 5 time normal value , bilirubin &gt; 3 time normal value ) , renal function ( creatinine clearance &lt; 30 ml / min ) Severe cardiovascular disease ( arrhythmias require chronic treatment , congestive heart failure leave ventricular ejection fraction &lt; 40 % ) Serious concurrent uncontrolled medical disorder Pregnant breast feed female patient Lack parent ' informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>